Erectile Dysfunction News and Research

Latest Erectile Dysfunction News and Research

A Medicare mistake: Paying for Viagra

The Department of Health and Human Services Office of the Inspector General concluded that the program paid more than $3 million in 2007 and 2008 for this drug, even though it is against the law for Medicare to pay for Viagra prescriptions.

16 Mar 2011

First Edition: March 15, 2011

Today's headlines include reports about the pace of legal challenges to the health law as well as ongoing congressional attempts to reach partisan agreement on a short-term budget bill to avert a government shutdown.

15 Mar 2011

Sildenafil helps improve exercise performance in children with congenital heart disease

Sildenafil, a drug used to treat erectile dysfunction and pulmonary hypertension, has another possible use—helping children and young adults with congenital heart disease to better tolerate exercise.

11 Mar 2011

5a-reductase inhibitors for male health problems can affect sexual health

A new study published in The Journal of Sexual Medicine reveals that, for the first time, 5a-reductase inhibitors commonly used to treat urinary problems in patients with benign prostatic hyperplasia (BPH) and found in popular medications to treat hair loss, can produce, persistent erectile dysfunction (ED), depression and loss of libido, even after the medication has been discontinued.

7 Mar 2011

Endo's FORTESTA Gel for treatment of 'Low T' in males is now available in pharmacies

Endo Pharmaceuticals announced that FORTESTA Gel – recently approved by the U.S. Food and Drug Administration for the treatment of low testosterone, or 'Low T' in adult males – is now available by prescription in pharmacies across the country.

3 Mar 2011

Study: Men who consume non-steroidals more likely to have erectile dysfunction

Men who take non-steroidal anti-inflammatory drugs three times a day for more than three months are 2.4 times more likely to have erectile dysfunction compared to men who do not take those drugs regularly, according to a Kaiser Permanente study published online in The Journal of Urology.

3 Mar 2011

EPO to grant patent for Apricus MycoVa product to treat nail fungus

Apricus Biosciences, Inc. announced today that the European Patent Office will grant a patent for the company's MycoVa product for treating onychomycosis.

2 Mar 2011

Endo fourth quarter total revenues increase 31% to $511 million

Endo Pharmaceuticals today reported financial results for the fourth quarter 2010.

28 Feb 2011

Nanoparticle therapy may improve survival after life-threatening blood loss

In an advance that could improve battlefield and trauma care, scientists at Albert Einstein College of Medicine of Yeshiva University have used tiny particles called nanoparticles to improve survival after life-threatening blood loss.

23 Feb 2011

Apricus Bio in discussions with FDA for PrevOnco SPA Phase III protocol

Apricus Biosciences, Inc., announced today that it is currently in discussions with the U.S. Food and Drug Administration ("FDA") relating to the PrevOnco™ Special Protocol Assessment ("SPA") Phase III protocol submitted by the Company in December 2010.

18 Feb 2011

Apricus Bio awards Neopharm exclusive rights to market and sell Vitaros in Israel and Palestinian Territories

Apricus Biosciences, Inc., announced today that it has entered into a licensing agreement granting Neopharm Group the exclusive rights to market and sell Vitaros®, Apricus Bio's treatment for erectile dysfunction ("ED") and, when and if available, its formulation for the treatment of premature ejaculation ("PE"), in Israel and the Palestinian Territories of the Gaza Strip and the West Bank.

15 Feb 2011

Myriad Genetics' 46-gene PROLARIS molecular diagnostic test predicts prostate cancer outcome

Myriad Genetics, Inc. announced today that a study published in Lancet Oncology shows the Company's 46-gene PROLARIS™ molecular diagnostic test significantly predicts prostate cancer outcome.

10 Feb 2011

Study: Fluorescent probe may serve as useful tool in future surgeries to repair injured nerves

Accidental damage to thin or buried nerves during surgery can have severe consequences, from chronic pain to permanent paralysis. Scientists at the University of California, San Diego School of Medicine may have found a remedy: injectable fluorescent peptides that cause hard-to-see peripheral nerves to glow, alerting surgeons to their location even before the nerves are encountered.

6 Feb 2011

NexMed presents data on NexACT technology use to improve less permeable, soluable oral drugs

Apricus Biosciences, today announced that its research and development team at its NexMed, USA, Inc. subsidiary is presenting data demonstrating the use of the Company's proprietary NexACT technology to improve less permeable or less soluable drugs, at the Controlled Release Society Product Development Forum for Poorly Soluble Drugs, being held January 27 to 29, 2011, in Miami, Florida.

29 Jan 2011

Lipocine files new patent applications in support of oral testosterone product for hypogonadism

Lipocine Inc. announced today that in addition to its issued patents involving oral testosterone, it has recently filed two new patent applications in support of its oral testosterone product for hypogonadism, also known as low testosterone (low T). These applications cover Lipocine's novel oral testosterone product (LPCN 1021) being developed to overcome the issues with currently marketed topical, parenteral, and transdermal testosterone products.

28 Jan 2011

FDA approves Clinical Data's Viibryd for major depressive disorder

Clinical Data, Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved vilazodone HCl tablets, to be marketed under the brand name Viibryd™, for the treatment of adults with major depressive disorder (MDD).

24 Jan 2011

VIVUS holds End-of-Review meeting with FDA for QNEXA NDA

VIVUS, Inc. today announced that it held an End-of-Review meeting with the Food and Drug Administration (FDA) for the New Drug Application (NDA) for QNEXA®, an investigational drug for the treatment of obesity. The meeting occurred on January 19th at the FDA's offices in Maryland and was attended by senior members of the FDA and VIVUS' management and consultants.

21 Jan 2011

Apricus Bio's MycoVa demonstrates 'non-inferiority' for treatment of onychomycosis compared to Loceryl

Apricus Biosciences, Inc. today announced that an additional analysis conducted on behalf of the Company has shown that MycoVa™ has successfully demonstrated 'non-inferiority' for the treatment of onychomycosis (commonly referred to as nail fungus), compared to the current standard of care in Europe for topical therapy, Loceryl®.

20 Jan 2011

AMS introduces STEP toolkit to help men with ED and SUI

American Medical Systems, a leading provider of world-class devices and therapies for male and female pelvic health, today announced the launch of its Solutions to Educate Patients Program in Europe.

18 Jan 2011

BPH, hair loss prevention drugs may produce adverse side effects in men

Researchers from Boston University School of Medicine, in collaboration with colleagues at Lahey Clinic and from Denmark and Germany, have found that 5a-reductase inhibitors, while improving urinary symptoms in patients with benign prostatic hyperplasia and possible hair loss prevention, produces significant adverse effects in some individuals including loss of libido, erectile dysfunction, ejaculatory dysfunction and potential depression.

12 Jan 2011

Erectile Dysfunction News and Research

Latest Erectile Dysfunction News and Research

A Medicare mistake: Paying for Viagra

First Edition: March 15, 2011

Sildenafil helps improve exercise performance in children with congenital heart disease

5a-reductase inhibitors for male health problems can affect sexual health

Endo's FORTESTA Gel for treatment of 'Low T' in males is now available in pharmacies

Study: Men who consume non-steroidals more likely to have erectile dysfunction

EPO to grant patent for Apricus MycoVa product to treat nail fungus

Endo fourth quarter total revenues increase 31% to $511 million

Nanoparticle therapy may improve survival after life-threatening blood loss

Apricus Bio in discussions with FDA for PrevOnco SPA Phase III protocol

Apricus Bio awards Neopharm exclusive rights to market and sell Vitaros in Israel and Palestinian Territories

Myriad Genetics' 46-gene PROLARIS molecular diagnostic test predicts prostate cancer outcome

Study: Fluorescent probe may serve as useful tool in future surgeries to repair injured nerves

NexMed presents data on NexACT technology use to improve less permeable, soluable oral drugs

Lipocine files new patent applications in support of oral testosterone product for hypogonadism

FDA approves Clinical Data's Viibryd for major depressive disorder

VIVUS holds End-of-Review meeting with FDA for QNEXA NDA

Apricus Bio's MycoVa demonstrates 'non-inferiority' for treatment of onychomycosis compared to Loceryl

AMS introduces STEP toolkit to help men with ED and SUI

BPH, hair loss prevention drugs may produce adverse side effects in men

The evolution of OCT for retinal imaging and disease intervention

Supercharging Next-Gen Antibody Discovery with AI and High-Throughput Experimentation

Prof. Dr. Kristina Kusche-Vihrog

Erectile Dysfunction News and Research

Latest Erectile Dysfunction News and Research

The evolution of OCT for retinal imaging and disease intervention

Supercharging Next-Gen Antibody Discovery with AI and High-Throughput Experimentation

Prof. Dr. Kristina Kusche-Vihrog

Newsletters you may be interested in